On Monday, Shares of Cisco Systems, Inc. (NASDAQ:CSCO), added 0.13% and closed at $30.22 in the last trading session. CSCO stock opened its last trade at $30.13 and after floating in a range of $30.10 to $3.42. The company’s Market capitalization is $151.58 Billion with the total Outstanding Shares of 5.03 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $22.46 and reached to max level of $31.95. Cisco ( NASDAQ : CSCO ) declared the appointment of Amy L. Chang, CEO and founder of Accompany, Inc., to its board of directors effective recently.
“We are very happy to have Amy join our board and look forward to her contributions,” said Chuck Robbins, CEO, Cisco. “Amy is a Silicon Valley leader and she understands the power we have to reimagine the way we can do business. Her experience as an entrepreneur, an engineer, and an industry disruptor will be invaluable to Cisco and to our customers in this new digital business environment.”
Chang, 39, is CEO and founder of Accompany, Inc., a relationship intelligence platform company. Before founding Accompany in 2013, Chang was with Google Inc. from 2005 to 2012, most recently serving as Global Head of Product, Google Ads Measurement and Reporting. Before Google, she held product administration and strategy positions at eBay Inc. Chang also formerly served as a consultant with McKinsey & Company, specializing in semiconductors, software and services. She holds a B.S. and an M.S., both in Electrical Engineering, from Stanford University. She presently serves on the board of directors of Splunk Inc.
“Drawing on her years of experience as a McKinsey consultant, advisor to numerous tech start-ups, an executive at Google, and now CEO of Accompany, Amy will provide fresh insights to our technology and business priorities as we continue to transform our business at an accelerated pace,” said Cisco Executive Chairman John Chambers.
Pfizer Inc. (NYSE:PFE), DROPPED -0.49% and closed at $32.50 in the last trading session. PFE stock opened its last trade at $32.58 and after floating in a range of $32.48 to $32.71. The company’s Market capitalization is $ 196.53 Billion with the total Outstanding Shares of 6.07 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $28.25 and reached to max level of $37.39. Pfizer Inc. (PFE) declared recently that the company will begin shipment of INFLECTRA® (infliximab-dyyb)for injection, a biosimilar of REMICADE®1 (infliximab) to wholesalers in the United States (U.S.) in late November 2016.
INFLECTRA will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the U.S. It is approved for the treatment of:
adult patients and pediatric patients (ages six years and older) with moderate to severely active Crohn’s disease who have had an inadequate response to conventional therapy;
adult patients with moderate to severely active ulcerative colitis who have had an inadequate response to conventional therapy; and
moderate to severely active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis.
“Biologics have revolutionized the treatment of many life-threatening and chronic diseases. By introducing INFLECTRA to the U.S. marketplace, Pfizer is assisting customers access an additional high quality treatment option that promises greater savings for the healthcare system,” said Diem Nguyen, regional president North America, Pfizer Essential Health Business. “We are proud of our global leadership in biosimilars, and will continue our efforts to advance a sustainable, competitive marketplace for these therapies to deliver a high quality, consistent supply of product and long-term savings and value for patients and physicians.”